StreetAlpha.app
Home › Stocks › KURA

Kura Oncology, Inc. (KURA)

Healthcare
$6.91
▼ −5.99%
LAST CLOSE · NOV 20

Kura Oncology develops targeted cancer medicines, including KOMZIFTI, an oral treatment for a form of acute myeloid leukemia. It last closed at $6.91 on Nov 20, down 5.99% on the day. The next earnings report for KURA is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, KURA reported EPS of -$0.78 on revenue of $22.8M, with revenue up 10.1% from a year ago. Over its last 8 reports the stock moved an average of 2.3% the session after earnings. Over the last 12 months KURA insiders bought $3.9M of stock on the open market and sold $4.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is KURA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KURA.

Key Stats

Last 12 months
Results
Revenue
$79.3M
Net income
−$292.9M
−369.3% margin
EPS (diluted)
−$3.30
Free cash flow
−$89.1M
−112.4% margin
Valuation
Market cap
$634.9M
91.9M shares
P/E
–
No P/E while losing money
Price to sales
8.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$57.9M
At Sep 30
Debt
$9.8M
At Sep 30
Shareholder equity
$18.0M
Shares outstanding
91.9M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $53.9M$53.9MFY2024FY2025: $67.5M$67.5MFY2025

From KURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$0.78
Quarter ended Sep 2026
Year ago EPS
-$0.85
Same quarter last year
Revenue
$22.8M
+10.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.22Dec '24Mar 2025: -$0.66Mar '25Jun 2025: -$0.75Jun '25Sep 2025: -$0.85Sep '25Dec 2025: -$0.92Dec '25Mar 2026: -$0.83Mar '26Jun 2026: -$0.77Jun '26Sep 2026: -$0.78Sep '26Latest -$0.78
Revenue by quarter
Mar 2025: $14.1MMar '25Jun 2025: $15.3MJun '25Sep 2025: $20.8MSep '25Dec 2025: $17.3MDec '25Mar 2026: $18.3MMar '26Jun 2026: $20.9MJun '26Sep 2026: $22.8MSep '26Latest $22.8M
How KURA moved after its last 8 reports
Average move the session after a report ±2.3%
Nov 10, 2026After the close+2.1%
Aug 12, 2026After the close+1.5%
May 12, 2026After the close−2.1%
Mar 5, 2026Time not announced−0.5%
Jan 12, 2026Time not announced−2.5%
Nov 4, 2025Time not announced+1.9%
Aug 7, 2025After the close−7.0%
May 1, 2025After the close−0.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on KURAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on KURA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on KURA

Technical Analysis

KURA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 21% below its 20 day and 40% below its 50 day average. It is 41% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the 52 week low at $6.75, and the nearest resistance the Pivot at $7.06.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.4%/day
Key levels
$13.9052 week high+101.2%
$10.43100 day average+50.9%
$9.76200 day average+41.2%
$9.6850 day average+40.1%
$8.3320 day average+20.5%
$8.26Swing high (Nov 11)+19.5%
$7.22Pivot R1+4.5%
$7.06Pivot+2.2%
$6.91Last close
$6.7552 week low−2.3%
$6.75Swing low (Nov 6)−2.3%
$6.74Pivot S1−2.5%
Indicators
RSI (14)33.29Weak, oversold below 30Neutral
MACD-0.78Below its signal lineBearish
Stochastic12.0Near the bottom of its rangeOversold
ADX (14)28.3Trending down
Williams %R-95.4Oversold below −80, overbought above −20Oversold
CCI (20)-76.8Oversold below −100, overbought above 100Neutral
Rate of change−5.0%Change over 10 sessionsBearish
ATR (14)$0.65Typical daily range, 9.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for KURA

What happened before

See how KURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow KURA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How KURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for KURAHow many large options trades hit KURA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

KURA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲125 buying vs 95 selling
  • ▲Held by funds +1.9 pts
  • ▲Funds holding +14
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding234220+6.4%
In funds' top 10330.0%
Held by funds96.8%94.9%+1.9 pts
New / increased40 / 8525 / 92+6.8%
Reduced / sold out70 / 2564 / 25+6.7%
Put/call ratio0.05––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KURA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

KURA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$3.9M3 buys · 1 insider
Sold$4.0M27 sales · 7 insiders
44% of the selling was under pre-arranged trading plans.
2025-12 sold $342K2026-01 sold $305K2026-05 sold $155K2026-06 sold $834K2026-08 bought $2.4M2026-08 sold $449K2026-09 sold $1.3M2026-11 bought $1.5M2026-11 sold $671KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19Brian T. PowlChief Commercial OfficerSale plan448$7.27$3K
Nov 17Kathleen FordCOOSale plan10,710$7.45$80K
Nov 17Brian T. PowlChief Commercial OfficerSale24,450$7.45$182K
Nov 17Mollie LeoniChief Medical OfficerSale41,250$7.45$307K
Nov 16Teresa Brophy BairChief Legal OfficerSale plan8,601$7.44$64K
Nov 16Thomas James DoyleSVP, Finance & AccountingSale4,697$7.44$35K
Every insider buy and sale for KURA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See KURA insider trades →

From SEC Form 4 filings by KURA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KURA is in one of them and how their past KURA trades turned out.

KURA in the AI portfolios
Loading…

KURA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KURA in an article yet. Here's the latest on the wider market.

KURA in the news

KURA Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jan 20
Who traded KURA · since 2022
Latest 1 filing
$1K – $15KTraded Dec 12, 2022Filed Jan 20, 2023
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYBuy$1K – $15KDec 12, 2022Jan 20, 202339 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Kura Oncology

Kura Oncology is a biopharmaceutical company based in San Diego, California, that develops targeted medicines for cancer and blood diseases. Its first approved product, KOMZIFTI, is taken by mouth to treat adults with relapsed or refractory acute myeloid leukemia who carry a susceptible NPM1 mutation. The company is also studying its drug candidates in solid tumors, including kidney, lung, colorectal and pancreatic cancers, often alongside standard treatments.

Headquarters
San Diego, CA